A Phase 1/2 interventional study of MEDI-551 and Rituximab in B-cell Malignancies and Cancer, sponsored by MedImmune LLC. Completed at 21 sites in 5 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-05-13.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551) in participants with advanced B-cell malignancies. Expansion to occur at maximum tolerated dose (MTD), or if not reached, at optimal biologic dose (OBD).
To determine the MTD or OBD of MEDI-551 in participants with relapsed or refractory advanced B-cell malignancies.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 136 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
First submitted after MedImmune LLC became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive intravenous (IV) infusion of MEDI 551 0.5 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Drug: MEDI-551
Participants will receive IV infusion of MEDI 551 1 mg/kg once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Drug: MEDI-551
Participants will receive IV infusion of MEDI 551 2 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Drug: MEDI-551
Participants will receive IV infusion of MEDI 551 4 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Drug: MEDI-551
Participants will receive IV infusion of MEDI 551 8 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Drug: MEDI-551
Participants will receive IV infusion of MEDI 551 12 mg/kg on Days 1 and 8 of Cycle 1 (loading doses) and then once every 28 days at the start of each subsequent cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Drug: MEDI-551
Participants will receive IV infusion of MEDI- 551 6 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Drug: MEDI-551
Participants will receive IV infusion of MEDI- 551 12 mg/kg weekly for 4 weeks during Cycle 1 (Days 1, 8, 15, and 22) and thereafter from Cycle 2 on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Drug: MEDI-551
Participants will receive IV infusion of MEDI- 551 24 mg/kg weekly for 4 weeks during Cycle 1 (over 2 days on Day 1 and Day 2, and on Days 8, 15, and 22) and thereafter from Cycle 2, on Day 1 of each 28-day cycle until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Drug: MEDI-551
Participants will receive IV infusion of MEDI- 551 8 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
Drug: MEDI-551 · Drug: Rituximab
Participants will receive IV infusion of MEDI- 551 12 mg/kg on Days 2 and 8 during Cycle 1 and on Day 1 during Cycle 2 (28-day cycle) in combination with rituximab 375 mg/m\^2 on Days 1, 8, 15, and 22. From Cycle 3 onwards, only MEDI- 551 8 mg/kg will be administered on Day 1 of each 28-day cycle. The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
Drug: MEDI-551 · Drug: Rituximab
Participants will receive IV infusion of MEDI-551 12 mg/kg on Days 1 and 8 of Cycle 1 and thereafter Day 1 of 28- day cycles from Cycle 2 onwards. Treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches CR or withdraws consent.
Drug: MEDI-551
MEDI-551 will be administered intravenously (IV) once every week in 4-week cycles until complete response, disease progression, toxicity, or another reason for treatment discontinuation will be observed.
Rituximab will be administered IV on Days 1, 8, 15, and 22 (28- day cycle). The treatment will be continued until the participants experiences unacceptable toxicity, disease progression, reaches complete response or withdraws consent.
Optimal Biologic Dose of MEDI-551 for Part A
Optimal biologic dose (OBD) was defined as the dose lower than the maximum tolerated dose (MTD), used for dose expansion. The MTD is defined as the highest dose at which less than equal to (\<=) 1 out of 6 participants experience a dose limiting toxicities (DLT) from the time of first administration of MEDI-551 through the first 28-day cycle.
Time frame: Day 1 to Day 28 of Cycle 1
Highest Protocol-defined Dose for Part B
Highest protocol-defined dose is dose of MEDI-551 in the absence of exceeding the MTD in participants with relapsed or rituximab-refractory chronic lymphocytic leukemia (defined as those with less than a partial response (PR) or progression within 6 months after completing therapy with rituximab). The MTD is defined as the highest dose at which \<= 1 out of 6 participants experience a DLT from the time of first administration of MEDI-551 through the first 28-day cycle.
Time frame: Day 1 to Day 28 of Cycle 1
Highest Protocol-defined Dose for Part C
Highest protocol-defined dose is the dose of MEDI-551 in combination with rituximab at the MTD or the highest protocol-defined dose in the absence of exceeding the MTD in participants with aggressive lymphomas. The MTD is defined as the highest dose at which \<= 1 out of 6 participants experience a DLT from the time of first administration of MEDI-551 through the first 28-day cycle.
Time frame: Day 1 to Day 28 of Cycle 1
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part A, Part B, and Part C
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Number of Participants With Dose Limiting Toxicities of MEDI-551 in Part A, Part B, and Part C
A dose limiting toxicities (DLT) for arm A, B, and C was defined as MEDI-551 (or rituximab for Arm C) treatment-related AE of any toxicity grade that led to an inability to receive a full cycle of MEDI-551 (or rituximab for Arm C) or any Grade 3 or higher toxicity (except Grade 3 fever, transient Grade 3 rigors or chills, Grade 3 tumor lysis syndrome, any Grade 3 or 4 electrolyte alteration, any Grade 3 liver function test elevation,\>= Grade 3 or 4 lymphopenia or leukopenia, \<= Grade 4 neutropenia, \<= Grade 4 thrombocytopenia, \<= Grade 4 anemia, and Grade 3 infusion-related reaction and infusion reaction), during DLT evaluable period.
Time frame: Day 1 to Day 28 of Cycle 1
Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part A, Part B, and Part C
Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine.
Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part A, Part B, and Part C
Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry).
Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part A, Part B, and Part C
Number of participants with abnormal electrocardiograms (ECGs) reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG.
Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Percentage of Participants With Complete Response for Part B, Part C, and Part D
Complete response (CR) is defined as disappearance of all evidence of disease according to International Working Group criteria (IWG). For nodal masses; fluorodeoxyglucose (FDG)-avid or polyethylene terephthalate (PET) positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on computed tomography (CT). For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry (IHC) was negative.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Percentage of Participants With Partial Response for Part B, Part C, and Part D
The PR is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Duration of Complete Response for Part B, Part C, and Part D
Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Percentage of Participants With Objective Response Rate for Part B, Part C, and Part D
Objective response rate (ORR) is proportion of participants with CR or partial response (PR) as per IWG criteria. CR is disappearance of all evidence of disease. Nodal masses; FDG-avid/PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. Spleen; not palpable, nodules disappeared. Bone marrow; infiltrate cleared on repeat biopsy; if unknown by morphology, IHC was negative. PR is regression of measurable disease and no new sites. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Duration of Objective Response for Part B, Part C, and Part D
Duration of objective response (DOR) is the first documentation of objective response to the first documented progressive disease (PD) or relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR.
Time frame: Cycle 1 Day 1, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Percentage of Participants With Disease Control Rate for Part B, Part C, and Part D
Disease control includes CR, PR, or stable disease (SD) for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. Nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. Spleen; not palpable, nodules disappeared. Bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. Nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules; no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy. SD is failure to attain CR/PR or PD.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Duration of Disease Control for Part B, Part C, and Part D
Duration of disease control is defined as the time period from start of MEDI-551 administration to the event of PD/relapse. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Time to Response for Part B, Part C, and Part D
Time to response (TTR) is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Progression Free Survival for Part B, Part C, and Part D
Progression-free survival (PFS) is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy. Kaplan-Meier method was used to evaluate PFS.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Overall Survival for Part B, Part C, and Part D
Overall survival (OS) is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) for Part D
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs in Part D
Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine.
Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part D
Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry).
Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part D
Number of participants with abnormal ECGs reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG.
Time frame: Day 1 through 90-Day Post Last Dose (Approximately 9 years)
Percentage of Participants With Complete Response for Part A
The CR is defined as disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Percentage of Participants With Partial Response for Part A
The PR is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Duration of Complete Response for Part A
Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Percentage of Participants With Objective Response Rate for Part A
The ORR is defined as proportion of participants with CR or PR according to IWG criteria. CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if unknown by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. For spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Duration of Objective Response for Part A
The DOR is the first documentation of objective response to the first documented PD or relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Percentage of Participants With Disease Control Rate for Part A
Disease control includes CR, PR, or SD for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG -avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. For spleen and liver: \>= 50% decrease in SPD of nodules; no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy. SD is failure to attain CR/PR or PD.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Duration of Disease Control for Part A
Duration of disease control is defined as the time period from start of MEDI-551 administration to the event of PD/relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Time to Response for Part A
The TTR is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Progression Free Survival for Part A
The PFS is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. Kaplan-Meier method was used to evaluate PFS. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Overall Survival for Part A
The OS is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS.
Time frame: Day 1 of all Cycles, then every 2 months during the first year of treatment and then every 6 months until end of treatment (unacceptable toxicity, disease progression, withdraws consent, whichever occurred first) (approximately 9 years)
Trough Serum Concentration of MEDI-551 by Treatment Cycle
Trough serum concentration (Ctrough) is defined as lowest concentration reached by a drug before the next dose is administered. The Ctrough concentration of MEDI-551 by treatment cycle is reported.
Time frame: For Part A: C1D1 of each cycles; For Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; For Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10;For Part D: C1D1, C1D8, then Day 1 of each cycle until Cycle 10
Peak Serum Concentration of MEDI-551 by Treatment Cycle
Peak serum concentration is concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose.
Time frame: For Part A: C1D1 of each cycles; For Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; For Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10;For Part D: C1D1, C1D8, then Day 1 of each cycle until Cycle 10
Area Under the Concentration Curve at Steady State (AUCss) of MEDI-551
Area under the concentration-time curve at steady state (Css, AUC) of MEDI-551 is reported.
Time frame: Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24
Apparent Clearance of MEDI-551
Apparent clearance of MEDI-551 is reported.
Time frame: Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24
Volume of Distribution of MEDI-551
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Central volume of distribution (Vd1) is defined as hypothetical volume into which a drug initially distributes upon administration and peripheral volume of distribution (Vd2) is defined as the sum of all tissue spaces outside the central compartment.
Time frame: Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24
Terminal Half-life (t1/2) of MEDI-551
Terminal half-life is the time required for the plasma concentration of MEDI-551 to fall by 50% during the terminal phase.
Time frame: Part A:Cycle(C)1 Day(D)1 (Pre & post dose [PPD] 2,6,24,48 hrs PD); PPD once a week in 4 weeks C till C71; Part B:C1 (D1,D8,D15,D22),PPD of D1 of each C till C28; Part C & D:PPD of C1 (D2,D8), predose D15 and 22, PPD of D1 of each C till C24
Number of Participants With Positive Anti-drug Antibodies (ADA) Titer to MEDI-551
Number of participants with positive Anti-drug antibodies (ADA) titer to MEDI-551 is reported.
Time frame: Part A:C1D1; Part B: C1D1; Part C: C1D1; Part D: C1D1; End of treatment (EOT); 90 Days post last dose (approximately 9 years)
B-cell Concentration in Serum
B-cell Concentration in serum is reported.
Time frame: Part A:C1D1 of each cycles; Part B: C1D1 of each cycle + C1D8, C1D15, and C1D22; Part C: C1D2, C1D8, then Day 1 of each cycle until Cycle 10; Part D: C1D1, C1D8, Day 1 of each cycle until Cycle 10; EOT;90 Days post last dose (approximately 9 years)
Immunoglobulin (Ig) Concentration in Serum
Immunoglobin (Ig) concentration in serum is reported.
Time frame: Part A:C1D1 of each cycles; EOT;90 Days post last dose (approximately 9 years)
| Milestone | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 4 | 3 | 6 | 3 | 76 | 3 | 3 | 1 | 3 | 17 | 14 |
| Completed | 0 | 0 | 0 | 1 | 0 | 9 | 0 | 1 | 0 | 0 | 6 | 3 |
| Not completed | 3 | 4 | 3 | 5 | 3 | 67 | 3 | 2 | 1 | 3 | 11 | 11 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 | 1 | 3 | 1 | 23 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Death | 0 | 2 | 2 | 1 | 2 | 30 | 1 | 0 | 1 | 2 | 9 | 8 |
| Withdrew: Other | 1 | 0 | 0 | 1 | 0 | 12 | 2 | 2 | 0 | 1 | 1 | 0 |
Optimal biologic dose (OBD) was defined as the dose lower than the maximum tolerated dose (MTD), used for dose expansion. The MTD is defined as the highest dose at which less than equal to (\<=) 1 out of 6 participants experience a dose limiting toxicities (DLT) from the time of first administration of MEDI-551 through the first 28-day cycle.
| mg/Kg | Part A-MEDI-551 Part A |
|---|---|
| Optimal Biologic Dose of MEDI-551 for Part A | 12 |
Highest protocol-defined dose is dose of MEDI-551 in the absence of exceeding the MTD in participants with relapsed or rituximab-refractory chronic lymphocytic leukemia (defined as those with less than a partial response (PR) or progression within 6 months after completing therapy with rituximab). The MTD is defined as the highest dose at which \<= 1 out of 6 participants experience a DLT from the time of first administration of MEDI-551 through the first 28-day cycle.
| mg/Kg | Part B-MEDI-551 |
|---|---|
| Highest Protocol-defined Dose for Part B | 24 |
Highest protocol-defined dose is the dose of MEDI-551 in combination with rituximab at the MTD or the highest protocol-defined dose in the absence of exceeding the MTD in participants with aggressive lymphomas. The MTD is defined as the highest dose at which \<= 1 out of 6 participants experience a DLT from the time of first administration of MEDI-551 through the first 28-day cycle.
| mg/kg | Part C-MEDI-551 + Rituximab |
|---|---|
| Highest Protocol-defined Dose for Part C | 12 |
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TEAEs | 3 | 4 | 3 | 6 | 3 | 76 | 3 | 3 | 1 | 3 | 17 |
| TESAEs | 1 | 1 | 2 | 1 | 1 | 23 | 1 | 2 | 1 | 1 | 9 |
A dose limiting toxicities (DLT) for arm A, B, and C was defined as MEDI-551 (or rituximab for Arm C) treatment-related AE of any toxicity grade that led to an inability to receive a full cycle of MEDI-551 (or rituximab for Arm C) or any Grade 3 or higher toxicity (except Grade 3 fever, transient Grade 3 rigors or chills, Grade 3 tumor lysis syndrome, any Grade 3 or 4 electrolyte alteration, any Grade 3 liver function test elevation,\>= Grade 3 or 4 lymphopenia or leukopenia, \<= Grade 4 neutropenia, \<= Grade 4 thrombocytopenia, \<= Grade 4 anemia, and Grade 3 infusion-related reaction and infusion reaction), during DLT evaluable period.
| Participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities of MEDI-551 in Part A, Part B, and Part C | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine.
| Participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | 0 | 2 | 0 | 0 | 1 | 6 | 0 | 1 | 1 | 0 | 4 |
| Blood fibrinogen decreased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Blood fibrinogen increased | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Febrile neutropenia | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 |
| Hematocrit decreased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin increased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Leukopenia | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Lymphocyte count decreased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Lymphopenia | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 0 |
| Myelocytosis | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Neutropenia | 0 | 0 | 0 | 1 | 1 | 14 | 1 | 1 | 0 | 1 | 2 |
| Neutrophil count abnormal | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Neutrophil count decreased | 1 | 1 | 0 | 1 | 0 | 5 | 0 | 1 | 1 | 0 | 2 |
| Platelet count decreased | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 1 | 0 | 1 |
| Red blood cell count decreased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reticulocytosis | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Thrombocytopenia | 0 | 1 | 0 | 3 | 0 | 6 | 0 | 1 | 0 | 0 | 2 |
| White blood cell count decreased | 0 | 0 | 0 | 1 | 1 | 3 | 0 | 2 | 1 | 0 | 2 |
| Hypergammaglobulinemia | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Activated PTT prolonged | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Leukocytosis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Alanine aminotransferase increased | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 1 | 0 | 1 |
| Aspartate aminotransferase increased | 0 | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 1 | 0 | 1 |
| Blood alkaline phosphatase increased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Blood chloride decreased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood creatinine increased | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 2 |
| Blood glucose decreased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Blood glucose increased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Blood lactate dehydrogenase increased | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 1 |
| Blood potassium decreased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Blood urea increased | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Blood uric acid increased | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Gamma-glutamyl transferase increased | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
| Hyperbilirubinemia | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypercalcemia | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 1 |
| Hyperglycemia | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Hyperkalemia | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hyperuricemia | 1 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 1 |
| Hypocalcemia | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
| Hypoglycemia | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Hypokalemia | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 1 |
| Hypomagnesemia | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 |
| Hyponatremia | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Protein total decreased | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Blood albumin decreased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypernatremia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Hypoalbuminemia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 |
| Haematuria | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Dysuria | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 2 |
| Pollakiuria | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Hemoglobinuria | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Hydronephrosis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Urinary incontinence | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry).
| Participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Bradycardia | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Chills | 0 | 0 | 0 | 1 | 0 | 5 | 0 | 1 | 0 | 0 | 1 |
| Dyspnea | 0 | 1 | 1 | 1 | 0 | 10 | 0 | 2 | 1 | 0 | 4 |
| Hypertension | 2 | 1 | 0 | 0 | 0 | 8 | 0 | 2 | 0 | 0 | 2 |
| Hypotension | 1 | 3 | 1 | 0 | 0 | 4 | 0 | 0 | 1 | 0 | 2 |
| Orthostatic hypotension | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Palpitations | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Pyrexia | 0 | 0 | 1 | 2 | 0 | 16 | 1 | 1 | 0 | 0 | 3 |
| Systolic hypertension | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
| Tachycardia | 0 | 0 | 0 | 0 | 0 | 6 | 1 | 0 | 0 | 0 | 1 |
Number of participants with abnormal electrocardiograms (ECGs) reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG.
| Participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sinus bradycardia | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Atrial fibrillation | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 |
| Mitral valve incompetence | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Supraventricular extrasystoles | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Tricuspid valve incompetence | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| ECG QT prolonged | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Atrial flutter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Atrial tachycardia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Supraventricular tachycardia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
Complete response (CR) is defined as disappearance of all evidence of disease according to International Working Group criteria (IWG). For nodal masses; fluorodeoxyglucose (FDG)-avid or polyethylene terephthalate (PET) positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on computed tomography (CT). For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, immunohistochemistry (IHC) was negative.
| Percentage of Participants | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Complete Response for Part B, Part C, and Part D | 33.3 (0.8 to 90.6) | 0 (0.0 to 70.8) | — | 33.3 (0.8 to 90.6) | 18.8 (4.0 to 45.6) | 0 (0.0 to 24.7) |
The PR is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.
| Percentage of Participants | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Partial Response for Part B, Part C, and Part D | 33.3 | 33.3 | — | 33.3 | 25.0 | 23.1 |
Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR.
| Months | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Duration of Complete Response for Part B, Part C, and Part D | NA (5.6 to 5.6) | — | — | NA (0.3 to 0.3) | NA (20.0 to 38.4) | — |
Objective response rate (ORR) is proportion of participants with CR or partial response (PR) as per IWG criteria. CR is disappearance of all evidence of disease. Nodal masses; FDG-avid/PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. Spleen; not palpable, nodules disappeared. Bone marrow; infiltrate cleared on repeat biopsy; if unknown by morphology, IHC was negative. PR is regression of measurable disease and no new sites. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.
| Percentage of participants | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response Rate for Part B, Part C, and Part D | 66.7 (9.4 to 99.2) | 33.3 (0.8 to 90.6) | — | 66.7 (9.4 to 99.2) | 43.8 (19.8 to 70.1) | 23.1 (5.0 to 53.8) |
Duration of objective response (DOR) is the first documentation of objective response to the first documented progressive disease (PD) or relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR.
| Months | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Duration of Objective Response for Part B, Part C, and Part D | NA (38.9 to 47.2) | 27.5 (27.5 to 27.5) | — | 3.7 (2.4 to 3.7) | NA (1.0 to 44.7) | 3.7 (1.9 to 27.2) |
Disease control includes CR, PR, or stable disease (SD) for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. Nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. Spleen; not palpable, nodules disappeared. Bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. Nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules; no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy. SD is failure to attain CR/PR or PD.
| Percentage of participants | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Disease Control Rate for Part B, Part C, and Part D | 100 (29.2 to 100) | 100 (29.2 to 100) | — | 100 (29.2 to 100) | 68.8 (41.3 to 89.0) | 46.2 (19.2 to 74.9) |
Duration of disease control is defined as the time period from start of MEDI-551 administration to the event of PD/relapse. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control.
| Months | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Duration of Disease Control for Part B, Part C, and Part D | NA (9.7 to 50.9) | 29.8 (22.6 to 39.5) | — | 5.5 (4.2 to 5.5) | 14.6 (1.7 to 46.5) | 3.8 (3.5 to 29.0) |
Time to response (TTR) is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR.
| Months | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Time to Response for Part B, Part C, and Part D | 6.5 (3.7 to 9.2) | 12.0 (12.0 to 12.0) | — | 1.8 (1.7 to 1.8) | 2.0 (1.7 to 17.3) | 1.8 (1.6 to 1.9) |
Progression-free survival (PFS) is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy. Kaplan-Meier method was used to evaluate PFS.
| Months | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Progression Free Survival for Part B, Part C, and Part D | NA (9.7 to 50.9) | 29.8 (22.6 to 39.5) | — | 5.5 (4.2 to 5.5) | 3.5 (0.7 to 46.5) | 2.0 (0.7 to 29.0) |
Overall survival (OS) is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS.
| Months | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Overall Survival for Part B, Part C, and Part D | NA (19.4 to 53.8) | NA (37.6 to 41.9) | — | 25.0 (18.3 to 45.4) | 33.4 (0.9 to 51.3) | 17.9 (1.2 to 38.9) |
An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
| Participants | Part D-MEDI-551 12 mg/kg |
|---|---|
| TEAEs | 14 |
| TESAEs | 5 |
Number of participants with clinical laboratory abnormalities reported as TEAEs are reported. Clinical laboratory abnormalities are defined as any abnormal findings in analysis of serum chemistry, hematology, and urine.
| Participants | Part D-MEDI-551 12 mg/kg |
|---|---|
| Anemia | 2 |
| Febrile neutropenia | 1 |
| Lymphocyte count decreased | 3 |
| Neutropenia | 1 |
| Neutrophil count decreased | 4 |
| Platelet count decreased | 1 |
| Polycythemia | 1 |
| Thrombocytopenia | 2 |
| White blood cell count decreased | 3 |
| Blood ALP increased | 1 |
| Blood bilirubin increased | 1 |
| Blood LDH increased | 1 |
| Blood potassium decreased | 1 |
| Hypercalcemia | 1 |
| Hyperglycemia | 2 |
| Hyperuricemia | 2 |
| Hypocalcemia | 1 |
| Hypokalemia | 2 |
| Pollakiuria | 1 |
| Urinary incontinence | 1 |
Number of participants with abnormal vital signs reported as TEAEs are reported. Abnormal vital signs are defined as any abnormal findings in the vital signs parameters (temperature, blood pressure, pulse rate, respiratory rate, and pulse oximetry).
| Participants | Part D-MEDI-551 12 mg/kg |
|---|---|
| Chills | 2 |
| Dyspnea | 1 |
| Hypertension | 1 |
| Hypotension | 1 |
| Palpitations | 1 |
| Pyrexia | 2 |
| Tachycardia | 1 |
Number of participants with abnormal ECGs reported as TEAEs are reported. Abnormal ECGs are defined as any abnormal findings in heart rate, RR interval, PR interval, QRS, axis, and QT intervals from the primary lead of the digital 12-lead ECG.
| Participants | Part D-MEDI-551 12 mg/kg |
|---|---|
| Number of Participants With Abnormal Electrocardiograms Reported as TEAEs in Part D | 1 |
The CR is defined as disappearance of all evidence of disease according to IWG criteria. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative .Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative.
| Percentage of Participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Complete Response for Part A | 33.3 (0.8 to 90.6) | 0 (0.0 to 60.2) | 0 (0.0 to 70.8) | 20.0 (0.5 to 71.6) | 0 (0.0 to 70.8) | 12.5 (5.9 to 22.4) |
The PR is defined as regression of measurable disease and no new sites according to IWG criteria. Nodal masses: \>= 50% decrease in sum of the product diameters (SPD) of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. Spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. Bone marrow: irrelevant if positive prior to therapy.
| Percentage of Participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Partial Response for Part A | 33.3 | 0 | 0 | 0 | 33.3 | 15.3 |
Duration of CR is from the first documentation of a CR to the time of progressive disease/relapse according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. Variably FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. Kaplan-Meier method was used to evaluate duration of CR.
| Months | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Duration of Complete Response for Part A | 7.1 (7.1 to 7.1) | — | — | 14.9 (14.9 to 14.9) | — | 14.3 (1.9 to 31.8) |
The ORR is defined as proportion of participants with CR or PR according to IWG criteria. CR is disappearance of all evidence of disease. For nodal masses; FDG-avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if unknown by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) FDG-avid or PET negative; regression on CT. For spleen and liver: \>= 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter); no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy.
| Percentage of participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Objective Response Rate for Part A | 66.7 (9.4 to 99.2) | 0 (0.0 to 60.2) | 0 (0.0 to 70.8) | 20.0 (0.5 to 71.6) | 33.3 (0.8 to 90.6) | 27.8 (17.9 to 39.6) |
The DOR is the first documentation of objective response to the first documented PD or relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate DOR.
| Months | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Duration of Objective Response for Part A | 8.8 (7.4 to 8.8) | — | — | 15.0 (15.0 to 15.0) | 3.0 (3.0 to 3.0) | 19.8 (0.0 to 41.9) |
Disease control includes CR, PR, or SD for at least 8 weeks according to IWG criteria. The CR is disappearance of all evidence of disease. For nodal masses; FDG -avid or PET positive prior to therapy; mass of any size permitted if PET negative. FDG-avid or PET negative; regression to normal size on CT. For spleen; not palpable, nodules disappeared. For bone marrow; infiltrate cleared on repeat biopsy; if indeterminate by morphology, IHC was negative. PR is regression of measurable disease and no new sites. For nodal masses: \>= 50% decrease in SPD of up to 6 largest dominant masses; no increase in size of other nodes (a) FDG-avid or PET positive prior to therapy; one or more PET positive at previously involved site (b) Variably FDG-avid or PET negative; regression on CT. For spleen and liver: \>= 50% decrease in SPD of nodules; no increase in size of liver or spleen. For bone marrow: irrelevant if positive prior to therapy. SD is failure to attain CR/PR or PD.
| Percentage of participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Percentage of Participants With Disease Control Rate for Part A | 66.7 (9.4 to 99.2) | 50.0 (6.8 to 93.2) | 66.7 (9.4 to 99.2) | 80.0 (28.4 to 99.5) | 66.7 (9.4 to 99.2) | 73.6 (61.9 to 83.3) |
Duration of disease control is defined as the time period from start of MEDI-551 administration to the event of PD/relapse according to IWG criteria. PD is defined as any new lesion or increase by \>=50% of previously involved sites from nadir. For nodal masses: appearance of a new lesion(s) \> 1.5 cm in any axis, \>= 50% increase in SPD of more than one node, or \>= 50% increase in longest diameter of a previously identified node \> 1 cm in short axis lesions PET positive if FDG-avid lymphoma or PET positive prior to therapy. For spleen: \> 50% increase from nadir in the SPD of any previous lesions. For bone marrow: New or recurrent involvement. Kaplan-Meier method was used to evaluate duration of disease control.
| Months | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Duration of Disease Control for Part A | 12.6 (1.4 to 12.6) | NA (9.4 to 21.0) | NA (3.5 to 7.4) | 10.9 (3.9 to 94.9) | 6.6 (2.8 to 6.6) | 18.0 (0.9 to 49.7) |
The TTR is measured from the start of MEDI-551 administration to the first documentation of response (CR or PR) and assessed in participants who have achieved objective response. Kaplan-Meier method was used to evaluate TTR.
| Months | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Time to Response for Part A | 3.7 (3.5 to 3.9) | — | — | 1.9 (1.9 to 1.9) | 3.6 (3.6 to 3.6) | 3.2 (0.3 to 22.6) |
The PFS is measured from the start of MEDI-551 treatment until the first documentation of disease progression, relapse or death, whichever occurs first. Kaplan-Meier method was used to evaluate PFS. The PFS was censored on the date of last disease assessment for participants who have no documented PD/relapse or death prior to data cutoff, dropout, or the initiation of alternative anticancer therapy.
| Months | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Progression Free Survival for Part A | 12.6 (1.4 to 12.6) | 5.9 (0.6 to 21.0) | 3.5 (1.6 to 9.9) | 4.9 (1.1 to 94.9) | 6.6 (2.1 to 6.6) | 11.3 (0.0 to 49.7) |
The OS is measured from the start of MEDI-551 treatment until death. For participants who are alive at the end of study or lost to follow-up, OS will be censored on the last date when participants were known to be alive. Kaplan-Meier method was used to evaluate OS.
| Months | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| Overall Survival for Part A | NA (1.4 to 21.5) | 44.6 (0.8 to 91.5) | 9.9 (2.8 to 9.9) | NA (1.7 to 94.9) | 8.1 (2.8 to 12.5) | 45.3 (0.7 to 83.5) |
Trough serum concentration (Ctrough) is defined as lowest concentration reached by a drug before the next dose is administered. The Ctrough concentration of MEDI-551 by treatment cycle is reported.
| μg/mL | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part A-MEDI-551 12 mg/kg (Expansion) | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 (C1) Day 1 (D1) | NA ± NA | 0.333 ± 0.665 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 2.97 ± 24.1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| C1D2 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| C1D8 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 46.5 ± 20.9 | 102 ± 25.0 | 125 ± NA | 58.0 ± 14.3 | 115 ± 38.0 | 109 ± 58.5 |
| C1D15 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 81.8 ± 38.3 | 197 ± 51.2 | 329 ± NA | NA ± NA | NA ± NA | NA ± NA |
| C1D22 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 116 ± 47.4 | 281 ± 29.5 | — | NA ± NA | NA ± NA | NA ± NA |
| C2D1 | 15.6 ± 0.823 | 25.9 ± 10.9 | 12.9 ± 4.55 | 59.4 ± 11.0 | 89.8 ± 64.9 | 166 ± 54.0 | 124 ± 64.8 | 122 ± 37.2 | 326 ± 68.0 | — | 52.4 ± 17.7 | 106 ± 28.8 | 114 ± 40.1 |
| C3D1 | 19.3 ± 3.33 | 26.9 ± 12.2 | 6.78 ± 2.01 | 43.0 ± 8.40 | 97.0 ± 94.5 | 149 ± 46.2 | 113 ± 70.3 | 57.6 ± 43.1 | 187 ± 80.6 | — | 44.7 ± 14.2 | 92.1 ± 30.7 | 93.9 ± 35.6 |
| C4D1 | 20.9 ± 6.69 | 36.5 ± 0.550 | 5.59 ± 0.146 | 37.9 ± 13.8 | 33.4 ± NA | 146 ± 55.5 | 113 ± 57.1 | 36.0 ± 31.6 | 134 ± 67.7 | — | 48.2 ± 20.8 | 113 ± 70.0 | 102 ± 61.5 |
| C5D1 | 26.6 ± 7.17 | 46.8 ± 8.03 | — | 56.9 ± 19.6 | 31.8 ± NA | 136 ± 19.3 | 117 ± 60.9 | 35.7 ± 32.0 | 121 ± 78.1 | — | 51.6 ± 2.64 | 102 ± 26.3 | 147 ± 105 |
| C6D1 | 29.1 ± 6.17 | 29.1 ± 17.3 | 11.7 ± NA | 32.0 ± NA | 33.7 ± NA | 138 ± 27.2 | 123 ± 67.9 | 37.3 ± 33.5 | 106 ± 54.6 | — | 45.9 ± NA | 100 ± 22.9 | 150 ± 116 |
| C7D1 | 31.4 ± 7.08 | 25.1 ± 27.8 | 9.93 ± NA | 38.2 ± NA | 27.9 ± NA | 144 ± 42.4 | 109 ± 64.2 | 28.1 ± 21.2 | 95.1 ± 54.4 | — | 45.3 ± NA | 108 ± 20.2 | 248 ± NA |
| C8D1 | 27.1 ± 14.9 | 28.0 ± 1.86 | 8.80 ± NA | 33.3 ± NA | — | 109 ± NA | 114 ± 63.8 | 30.8 ± 30.4 | 86.8 ± 54.4 | — | — | 147 ± 82.2 | 177 ± NA |
| C9D1 | 21.6 ± NA | 31.6 ± 1.23 | 10.7 ± NA | 33.6 ± NA | — | 124 ± 23.2 | 121 ± 77.5 | 27.3 ± 27.1 | 94.8 ± 69.4 | — | — | 95.0 ± 7.59 | 192 ± 25.9 |
| C10D1 | 17.6 ± NA | 25.1 ± NA | 10.6 ± NA | 32.9 ± NA | — | 98.3 ± 5.05 | 139 ± 80.4 | 33.4 ± 34.8 | 84.2 ± 57.4 | — | — | 113 ± 27.6 | 215 ± NA |
Peak serum concentration is concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administrated and before the administration of a second dose.
| μg/mL | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part A-MEDI-551 12 mg/kg (Expansion) | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 (C1) Day 1 (D1) | 12.3 ± 1.20 | 22.8 ± 1.24 | 46.0 ± 22.2 | 100 ± 11.0 | 166 ± 59.5 | 280 ± 99.1 | 240 ± 90.0 | 122 ± 24.2 | 335 ± 79.1 | 199 ± NA | NA ± NA | NA ± NA | 260 ± 87.3 |
| C1D2 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 160 ± 23.5 | 214 ± 79.9 | NA ± NA |
| C1D8 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 162 ± 17.3 | 393 ± 80.8 | 470 ± NA | 246 ± 76.1 | 115 ± 38.0 | 303 ± 97.4 |
| C1D15 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 182 ± 31.1 | 517 ± 135 | 619 ± NA | NA ± NA | NA ± NA | NA ± NA |
| C1D22 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 208 ± 46.7 | 533 ± 223 | — | NA ± NA | NA ± NA | NA ± NA |
| C2D1 | 27.5 ± 0.752 | 43.9 ± 13.2 | 48.8 ± 21.7 | 149 ± 29.7 | 238 ± 106 | 467 ± 114 | 350 ± 130 | 186 ± 116 | 749 ± 133 | — | 205 ± 33.5 | 304 ± 108 | 333 ± 72.7 |
| C3D1 | 26.3 ± 2.20 | 46.4 ± 16.6 | 58.7 ± 0.783 | 145 ± 31.2 | 260 ± 89.6 | 374 ± 116 | 326 ± 110 | 155 ± 38.2 | 374 ± 125 | — | 192 ± 78.1 | 311 ± 74.0 | 277 ± 95.7 |
| C4D1 | 30.3 ± 5.46 | 48.3 ± 12.7 | 63.7 ± 35.1 | 161 ± 85.6 | 201 ± NA | 359 ± 115 | 342 ± 119 | 156 ± 81.7 | 384 ± 169 | — | 212 ± 84.1 | 261 ± 99.4 | 295 ± 116 |
| C5D1 | 39.4 ± 6.85 | 70.8 ± 5.43 | — | 151 ± 58.1 | 203 ± NA | 372 ± 113 | 347 ± 98.1 | 153 ± 71.6 | 363 ± 261 | — | 250 ± 82.3 | 290 ± 66.0 | 338 ± 245 |
| C6D1 | 40.4 ± 3.87 | 34.4 ± 4.21 | 43.2 ± NA | 123 ± NA | 198 ± NA | 345 ± 101 | 337 ± 82.1 | 130 ± 45.7 | 349 ± 140 | — | 209 ± NA | 332 ± 102 | 303 ± 237 |
| C7D1 | 41.3 ± 4.72 | 39.5 ± 30.8 | 41.0 ± NA | 123 ± NA | 182 ± NA | 383 ± 54.6 | 355 ± 95.7 | 174 ± 60.4 | 333 ± 133 | — | 235 ± NA | 392 ± 93.0 | 502 ± NA |
| C8D1 | 29.9 ± 12.3 | 58.2 ± 16.9 | 32.2 ± NA | 130 ± NA | — | 409 ± NA | 367 ± 102 | 164 ± 52.0 | 342 ± 173 | — | — | 317 ± 150 | 511 ± NA |
| C9D1 | 32.2 ± NA | 46.8 ± 5.58 | 37.8 ± NA | 127 ± NA | — | 391 ± 79.6 | 394 ± 125 | 159 ± 64.7 | 299 ± 69.8 | — | — | 363 ± 90.3 | 593 ± 200 |
| C10D1 | 43.3 ± NA | 33.5 ± NA | 42.3 ± NA | 133 ± NA | — | 307 ± 49.8 | 394 ± 157 | 166 ± 64.1 | 316 ± 189 | — | — | 349 ± 70.4 | 484 ± NA |
Area under the concentration-time curve at steady state (Css, AUC) of MEDI-551 is reported.
| μg⋅day/mL | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part A-MEDI-551 12 mg/kg (Expansion) | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Area Under the Concentration Curve at Steady State (AUCss) of MEDI-551 | 212 ± 28.1 | 287 ± 110 | 479 ± 57.7 | 1660 ± 778 | 2880 ± 2190 | 5720 ± 1620 | 4850 ± 1720 | 1730 ± 1030 | 4920 ± 1440 | NA ± NA | 2240 ± 338 | 4260 ± 1340 | 4250 ± 2000 |
Apparent clearance of MEDI-551 is reported.
| mL/day | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part A-MEDI-551 12 mg/kg (Expansion) | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apparent Clearance of MEDI-551 | 206 ± 101 | 302 ± 173 | 373 ± 70.9 | 210 ± 28.9 | 268 ± 126 | 198 ± 44.3 | 235 ± 110 | 303 ± 108 | 243 ± 81.6 | 279 ± NA | 288 ± 43.0 | 235 ± 87.5 | 237 ± 72.5 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Central volume of distribution (Vd1) is defined as hypothetical volume into which a drug initially distributes upon administration and peripheral volume of distribution (Vd2) is defined as the sum of all tissue spaces outside the central compartment.
| mL | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part A-MEDI-551 12 mg/kg (Expansion) | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vd1 | 3970 ± 851 | 3920 ± 491 | 4350 ± 948 | 4070 ± 464 | 4210 ± 510 | 4230 ± 234 | 4450 ± 889 | 3560 ± 286 | 4490 ± 947 | 5690 ± NA | 4520 ± 126 | 4350 ± 851 | 4510 ± 647 |
| Vd2 | 2670 ± 351 | 2010 ± 1080 | 1980 ± 888 | 2290 ± 767 | 2620 ± 1240 | 2920 ± 1070 | 3430 ± 2250 | 3290 ± 1440 | 2640 ± 1840 | 3670 ± NA | 4590 ± 847 | 2640 ± 1200 | 3200 ± 1440 |
Terminal half-life is the time required for the plasma concentration of MEDI-551 to fall by 50% during the terminal phase.
| Days | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part A-MEDI-551 12 mg/kg (Expansion) | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Terminal Half-life (t1/2) of MEDI-551 | 26.0 ± 6.88 | 17.3 ± 7.65 | 13.3 ± 6.41 | 22.1 ± 3.26 | 21.7 ± 8.65 | 27.9 ± 9.08 | 28.9 ± 15.0 | 19.9 ± 9.34 | 23.8 ± 10.9 | 25.1 ± NA | 25.3 ± 4.40 | 23.6 ± 9.38 | 25.6 ± 7.96 |
Number of participants with positive Anti-drug antibodies (ADA) titer to MEDI-551 is reported.
| Participants | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| EOT | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 90 Day Post Dose | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
B-cell Concentration in serum is reported.
No measurements were reported for this outcome.
Immunoglobin (Ig) concentration in serum is reported.
| mg/dL | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|
| C1D1 | 120.00 ± 46.36 | 110.00 ± 76.25 | 81.00 ± 66.36 | 61.67 ± 54.52 | 93.33 ± 46.11 | 93.01 ± 88.56 |
| C2D1 | 67.50 ± 7.78 | 113.67 ± 92.81 | 67.67 ± 58.05 | 57.00 ± 47.05 | 74.50 ± 47.38 | 88.90 ± 92.05 |
| C3D1 | 62.50 ± 6.36 | 106.00 ± 87.93 | 31.00 ± 29.70 | 57.25 ± 48.29 | 76.50 ± 50.20 | 67.90 ± 66.59 |
| C4D1 | 64.00 ± 9.90 | 152.50 ± 13.44 | 31.00 ± 33.94 | 63.67 ± 56.52 | 98.00 ± NA | 66.84 ± 61.83 |
| C5D1 | 69.00 ± 11.31 | 145.50 ± 38.89 | 50.00 ± NA | 58.67 ± 45.17 | 77.00 ± NA | 69.24 ± 70.45 |
| C6D1 | 63.50 ± 13.44 | 156.00 ± 48.08 | — | 41.00 ± NA | 71.00 ± NA | 62.86 ± 65.04 |
| C7D1 | 56.00 ± 1.41 | 127.00 ± NA | 47.00 ± NA | 41.00 ± NA | 61.00 ± NA | 67.26 ± 69.36 |
| C8D1 | 47.00 ± 7.07 | 147.00 ± 28.28 | 45.00 ± NA | 41.00 ± NA | — | 73.76 ± 66.87 |
| C9D1 | 51.00 ± NA | 137.50 ± 30.41 | 46.00 ± NA | 41.00 ± NA | — | 62.35 ± 61.90 |
| C10D1 | 47.00 ± NA | 155.00 ± NA | 46.00 ± NA | 41.00 ± NA | — | 73.17 ± 66.34 |
| EOT | 43.50 ± 12.02 | 96.00 ± 80.58 | 7.00 ± NA | 54.40 ± 46.55 | 65.33 ± 19.76 | 217.25 ± 1003.38 |
| 90 Days Post Dose | 49.00 ± NA | 84.50 ± 60.10 | — | 93.33 ± 42.06 | — | 45.20 ± 38.72 |
Collected over Day 1 through 90-Day Post Last Dose (Approximately 9 years). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A-MEDI-551 0.5 mg/kg | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A-MEDI-551 1 mg/kg | 2/4 (50%) | 1/4 (25%) | 4/4 (100%) |
| Part A-MEDI-551 2 mg/kg | 2/3 (66.7%) | 2/3 (66.7%) | 3/3 (100%) |
| Part A-MEDI-551 4 mg/kg | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Part A-MEDI-551 8 mg/kg | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Part A-MEDI-551 12 mg/kg | 30/76 (39.5%) | 23/76 (30.3%) | 75/76 (98.7%) |
| Part B-MEDI-551 6 mg/kg | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Part B-MEDI-551 12 mg/kg | 0/3 (0%) | 2/3 (66.7%) | 3/3 (100%) |
| Part B-MEDI-551 24 mg/kg | 1/1 (100%) | 1/1 (100%) | 1/1 (100%) |
| Part C-MEDI-551 8 mg/kg + Rituximab | 2/3 (66.7%) | 1/3 (33.3%) | 3/3 (100%) |
| Part C-MEDI-551 12 mg/kg + Rituximab | 9/17 (52.9%) | 9/17 (52.9%) | 17/17 (100%) |
| Part D-MEDI-551 12 mg/kg | 8/14 (57.1%) | 5/14 (35.7%) | 14/14 (100%) |
| Event | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 1/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/76 | 0/3 | 0/3 | 1/1 | 0/3 | 0/17 | 0/14 |
| Deep vein thrombosisVascular disorders | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/76 | 0/3 | 0/3 | 1/1 | 0/3 | 0/17 | 0/14 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 1/76 | 0/3 | 1/3 | 0/1 | 0/3 | 1/17 | 0/14 |
| PancreatitisGastrointestinal disorders | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/76 | 0/3 | 1/3 | 0/1 | 0/3 | 0/17 | 0/14 |
| CholecystitisHepatobiliary disorders | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/76 | 0/3 | 1/3 | 0/1 | 0/3 | 0/17 | 0/14 |
| BronchitisInfections and infestations | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/76 | 0/3 | 1/3 | 0/1 | 0/3 | 1/17 | 1/14 |
| GastroenteritisInfections and infestations | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 1/76 | 1/3 | 0/3 | 0/1 | 0/3 | 0/17 | 0/14 |
| PneumoniaInfections and infestations | 0/3 | 0/4 | 0/3 | 1/6 | 0/3 | 2/76 | 0/3 | 1/3 | 0/1 | 0/3 | 1/17 | 2/14 |
| VaricellaInfections and infestations | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/76 | 0/3 | 1/3 | 0/1 | 0/3 | 0/17 | 0/14 |
| Back painMusculoskeletal and connective tissue disorders | 1/3 | 0/4 | 0/3 | 0/6 | 0/3 | 1/76 | 0/3 | 0/3 | 0/1 | 0/3 | 0/17 | 0/14 |
| Event | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/3 | 2/4 | 0/3 | 0/6 | 1/3 | 6/76 | 0/3 | 1/3 | 1/1 | 0/3 | 4/17 | 2/14 |
| Vision blurredEye disorders | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 2/76 | 0/3 | 0/3 | 1/1 | 0/3 | 0/17 | 0/14 |
| DiarrhoeaGastrointestinal disorders | 3/3 | 2/4 | 1/3 | 0/6 | 0/3 | 18/76 | 1/3 | 2/3 | 1/1 | 1/3 | 5/17 | 3/14 |
| Dry mouthGastrointestinal disorders | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 2/76 | 0/3 | 0/3 | 1/1 | 0/3 | 1/17 | 1/14 |
| FatigueGeneral disorders | 1/3 | 1/4 | 1/3 | 2/6 | 3/3 | 28/76 | 2/3 | 3/3 | 0/1 | 1/3 | 9/17 | 5/14 |
| Oedema peripheralGeneral disorders | 0/3 | 1/4 | 0/3 | 0/6 | 0/3 | 8/76 | 0/3 | 2/3 | 1/1 | 0/3 | 5/17 | 2/14 |
| ContusionInjury, poisoning and procedural complications | 0/3 | 0/4 | 1/3 | 1/6 | 0/3 | 2/76 | 0/3 | 0/3 | 1/1 | 0/3 | 2/17 | 0/14 |
| FallInjury, poisoning and procedural complications | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/76 | 0/3 | 0/3 | 1/1 | 0/3 | 1/17 | 1/14 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/3 | 0/4 | 0/3 | 2/6 | 0/3 | 34/76 | 1/3 | 2/3 | 1/1 | 0/3 | 1/17 | 4/14 |
| Rib fractureInjury, poisoning and procedural complications | 0/3 | 0/4 | 0/3 | 0/6 | 0/3 | 0/76 | 0/3 | 0/3 | 1/1 | 0/3 | 0/17 | 0/14 |
Safety population included all participants who received any treatment of MEDI-551.
| Age, Continuous(Years) | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg | TOTAL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 66.0 ± 19.5 | 69.5 ± 12.5 | 64.7 ± 18.3 | 63.8 ± 12.7 | 60.0 ± 12.1 | 64.4 ± 11.2 | 61.3 ± 20.8 | 70.0 ± 7.0 | 78.0 ± NA | 68.0 ± 11.8 | 69.4 ± 10.8 | 67.9 ± 11.0 | 65.7 ± 11.5 |
| Sex: Female, Male(Participants) | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg | TOTAL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 0 | 1 | 2 | 1 | 30 | 1 | 1 | 1 | 1 | 10 | 5 | 55 |
| Male | 1 | 4 | 2 | 4 | 2 | 46 | 2 | 2 | 0 | 2 | 7 | 9 | 81 |
| Ethnicity (NIH/OMB)(Participants) | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg | TOTAL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 6 |
| Not Hispanic or Latino | 3 | 4 | 3 | 6 | 3 | 70 | 3 | 3 | 1 | 3 | 17 | 14 | 130 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Part A-MEDI-551 0.5 mg/kg | Part A-MEDI-551 1 mg/kg | Part A-MEDI-551 2 mg/kg | Part A-MEDI-551 4 mg/kg | Part A-MEDI-551 8 mg/kg | Part A-MEDI-551 12 mg/kg | Part B-MEDI-551 6 mg/kg | Part B-MEDI-551 12 mg/kg | Part B-MEDI-551 24 mg/kg | Part C-MEDI-551 8 mg/kg + Rituximab | Part C-MEDI-551 12 mg/kg + Rituximab | Part D-MEDI-551 12 mg/kg | TOTAL |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 | 0 | 5 | 0 | 1 | 0 | 0 | 0 | 0 | 8 |
| White | 3 | 3 | 3 | 5 | 3 | 68 | 3 | 2 | 1 | 2 | 15 | 14 | 122 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 1 | 0 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2010 to primary completion in Mar 2019, 107 months.
Results were first posted in May 2020, 1 year 1 month after primary completion.
Of 195 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's 107 months is above that.
Counting every sponsor, half of 297 studies reached it within 60 months; a quarter within 39 and three quarters within 89.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inebilizumab